低剂量盐酸米诺环素缓释剂联合Vitapex治疗侵袭性牙周炎的疗效观察

Clinical observation of low dose minocycline hydrochloride sustained-release agent combined with Vitapex in the treatment of invasive periodontitis

目的研究低剂量盐酸米诺环素缓释剂联合比塔派克斯糊剂(Vitapex)治疗侵袭性牙周炎的疗效,为侵蚀性牙周炎提供临床资料。方法选择80例侵蚀性牙周炎患者随机分为两组,分别为对照组(根管治疗)、试验组(盐酸米诺环素缓释剂联合Vitapex治疗),比较两组治疗前后肿瘤坏死因子(TNF-α)、白细胞介素17(IL-17)、C反应蛋白(CRP)、免疫球蛋白(IgG)含量的临床疗效自评的统计学差异。结果两组治疗前后TNF-α、IL-17、CRP、IgG1、IgG2a含量、PD、GI、BI指数比较,差异有统计学意义(P<0.05);随着时间迁移,TNF-α、IL-17、CRP、IgG2a含量、PD、GI、BI指数呈现下降趋势,IgG1含量呈现上升趋势。治疗后比较,试验组生化指标含量(TNF-α、IL-17、CRP、IgG2a)、PD、GI、BI低于对照组,差异有统计学意义(P<0.05);IgG1含量高于对照组。试验组临床疗效优于对照组,且有效率高于对照组,差异具有统计学意义(P<0.05)。结论低剂量盐酸米诺环素缓释剂联合Vitapex治疗侵袭性牙周炎明显比根管治疗效果更佳,值得临床推广。

Objective To study the efficacy of minocycline hydrochloride sustained-release agent combined with Vitapex in the treatment of invasive periodontitis.Methods 80 patients with erosive periodontitis were randomly divided into two groups.Control group(root canal therapy group)and experimental group(minocycline hydrochloride sustained-release agent combined with Vitapex treatment group)were used to compare the clinical efficacy of TNF-α,IL-17,CRP before and after treatment.ResultsThe two groups of patients before and after treatment TNF-α,IL-17,CRP levels of the statistical difference.The content of IgG1,IgG2a and the content of PD,GI,BI were significantly different(P<0.05),and the content of TNF-α,IL-17,IgG2a showed a significant downward trend.The content of IgG1 in the experimental group was significantly higher than that in the control group(P<0.05).The content of TNF-α,IL-17,IgG2a in the experimental group was significantly lower than that in the control group(P<0.05),and the content of PD,GI,BI in the experimental group was significantly lower than that in the control group(P<0.05).The clinical effect of the experimental group was significantly better than that of the control group.The effective rate was significantly higher than that of the control group(P<0.05).ConclusionsLow dose minocycline hydrochloride combined with Vitapex is more effective than root canal therapy in the treatment of invasive periodontitis.